AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15189519 — intervention group
Group type: COMPARATOR
Intervention: Traditional right-sided pacing sites (right ventricular apex and right atrial appendage)
Number of subjects: 0
Study 11378344 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone + Vinorelbine (MV)
Number of subjects: 281
Study 11378344 — intervention group
Group type: COMPARATOR
Intervention: 5‐fluorouracil + cyclophosphamide + doxorubicin/epirubicin (FAC/FEC)
Number of subjects: 281
Study 10332317 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 21
Study 10332317 — intervention group
Group type: COMPARATOR
Intervention: Rest (Control)
Number of subjects: 21
Study 8352508 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate laparoscopy
Number of subjects: 65
Study 8352508 — intervention group
Group type: COMPARATOR
Intervention: Laboratory contrast or imaging approach
Number of subjects: 65
Study 3544892 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (25 mg/kg orally over three days)
Number of subjects: 14
Study 3544892 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (25 mg/kg orally over three days)
Number of subjects: 14
Study 29704487 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 357
Study 29704487 — intervention group
Group type: COMPARATOR
Intervention: Routine management
Number of subjects: 357
Study 26408398 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat talk
Number of subjects: 85
Study 26408398 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive body talk
Number of subjects: 85
Study 26408398 — intervention group
Group type: COMPARATOR
Intervention: Neutral talk
Number of subjects: 85
Study 24759586 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable circumcision suture device (DCSD)
Number of subjects: 942
Study 24759586 — intervention group
Group type: COMPARATOR
Intervention: Conventional circumcision
Number of subjects: 942
Study 22640511 — intervention group
Group type: EXPERIMENTAL
Intervention: Extension of the intensive phase by 1 month
Number of subjects: 1871
Study 22640511 — intervention group
Group type: COMPARATOR
Intervention: No extension of the intensive phase
Number of subjects: 1871
Study 20800193 — intervention group
Group type: EXPERIMENTAL
Intervention: Defocused extracorporeal shock wave therapy (ESWT, 100 impulses/cm(2) at 0.1 mJ/mm(2)) applied once to the donor site, immediately after skin harvest
Number of subjects: 28
Study 20800193 — intervention group
Group type: COMPARATOR
Intervention: Standard topical therapy (nonadherent silicone mesh and antiseptic gel) without ESWT
Number of subjects: 28
Study 18304131 — intervention group
Group type: EXPERIMENTAL
Intervention: 3M Steri‐Strip S Surgical Skin Closure System
Number of subjects: 26
Study 18304131 — intervention group
Group type: COMPARATOR
Intervention: Subcuticular suture closure with a skin sealant
Number of subjects: 26
Study 16567984 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine exposure in utero for >7.5 weeks
Number of subjects: 1408
Study 16567984 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine exposure
Number of subjects: 1408
Study 16567984 — intervention group
Group type: EXPERIMENTAL
Intervention: Total and postnatal duration of zidovudine exposure
Number of subjects: 1408
Study 12706439 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg daily for 6 weeks
Number of subjects: 63
Study 10736124 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (NAC) administered for 100 minutes (150 mg/kg over 1 hour followed by 14 mg/kg per hour for 40 minutes)
Number of subjects: 0
Study 10736124 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose in water (control)
Number of subjects: 0
Study 9369111 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 liters of polyethylene glycol solution combined with a laxative (Group A)
Number of subjects: 100
Study 9369111 — intervention group
Group type: COMPARATOR
Intervention: 4 liters of polyethylene glycol solution (Group B)
Number of subjects: 100
Study 1396535 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) monotherapy
Number of subjects: 29
Study 1396535 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (PHT) monotherapy
Number of subjects: 29
Study 3994616 — intervention group
Group type: EXPERIMENTAL
Intervention: dimenhydrinate (50 mg)
Number of subjects: 70
Study 3994616 — intervention group
Group type: EXPERIMENTAL
Intervention: promethazine hydrochloride (25 mg)
Number of subjects: 70
Study 3994616 — intervention group
Group type: EXPERIMENTAL
Intervention: mixture (25 mg promethazine plus 10 mg d-amphetamine)
Number of subjects: 70
Study 3994616 — intervention group
Group type: EXPERIMENTAL
Intervention: dimenhydrinate (100 mg)
Number of subjects: 70
Study 3994616 — intervention group
Group type: EXPERIMENTAL
Intervention: promethazine (50 mg)
Number of subjects: 70
Study 3994616 — intervention group
Group type: COMPARATOR
Intervention: lactose placebo
Number of subjects: 70
Study 30023451 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing and Cognitive Behavioural Therapy (MI-CBT) in addition to Treatment as Usual (TAU)
Number of subjects: 0
Study 30023451 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) alone
Number of subjects: 0
Study 30023451 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-CBT
Number of subjects: 0
Study 30023451 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 0
Study 28701387 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate iron status (serum ferritin 12-75 μg/L)
Number of subjects: 745
Study 28701387 — intervention group
Group type: EXPERIMENTAL
Intervention: High iron status (serum ferritin ≥75 μg/L)
Number of subjects: 745
Study 28701387 — intervention group
Group type: EXPERIMENTAL
Intervention: High iron status with inflammation-corrected serum ferritin
Number of subjects: 745
Study 28701387 — intervention group
Group type: EXPERIMENTAL
Intervention: High iron status with normal serum soluble transferrin receptor concentration (<8.3 mg/L)
Number of subjects: 745
Study 28701387 — intervention group
Group type: COMPARATOR
Intervention: Deficient iron status (serum ferritin <12 or <15 μg/L)
Number of subjects: 745
Study 25512653 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation with lower tidal volumes
Number of subjects: 1348
Study 25512653 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation with higher tidal volumes
Number of subjects: 1348
Study 24093978 — intervention group
Group type: EXPERIMENTAL
Intervention: Ormeloxifene 30 mg, twice a week for 3 months
Number of subjects: 151
Study 24093978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 21962052 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 L O2 · min(‐1)
Number of subjects: 0
Study 21962052 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 L O2 · min(‐1)
Number of subjects: 0
Study 21962052 — intervention group
Group type: COMPARATOR
Intervention: Control (no oxygen supplementation during the first walk test)
Number of subjects: 0
Study 18267048 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-neomycin cream and nasal cautery
Number of subjects: 88
Study 18267048 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-neomycin cream alone
Number of subjects: 88
Study 18267048 — intervention group
Group type: EXPERIMENTAL
Intervention: No treatment
Number of subjects: 88
Study 18267048 — intervention group
Group type: COMPARATOR
Intervention: Control group (cautery only)
Number of subjects: 88
Study 16894588 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-resistant late-onset depressive disorder
Number of subjects: 29
Study 16894588 — intervention group
Group type: COMPARATOR
Intervention: Treatment-responsive late-onset depressive disorder
Number of subjects: 29
Study 12853504 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 24 microg bid
Number of subjects: 442
Study 12853504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 442
Study 10372230 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 60
Study 10372230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9046503 — intervention group
Group type: EXPERIMENTAL
Intervention: External cooling system with physiological saline
Number of subjects: 50
Study 9046503 — intervention group
Group type: EXPERIMENTAL
Intervention: External cooling system with bupivacaine/morphine
Number of subjects: 50
Study 9046503 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (physiological saline)
Number of subjects: 50
Study 2001806 — intervention group
Group type: EXPERIMENTAL
Intervention: Portacaval anastomosis
Number of subjects: 82
Study 2001806 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy
Number of subjects: 82
Study 6305479 — intervention group
Group type: EXPERIMENTAL
Intervention: Glioblastoma multiforme (GBM)
Number of subjects: 503
Study 6305479 — intervention group
Group type: EXPERIMENTAL
Intervention: Astrocytoma with atypical or anaplastic features (AAF)
Number of subjects: 503
Study 6305479 — intervention group
Group type: EXPERIMENTAL
Intervention: Astrocytoma Grade 3
Number of subjects: 503
Study 6305479 — intervention group
Group type: EXPERIMENTAL
Intervention: Astrocytoma Grade 4
Number of subjects: 503
Study 30870563 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious Illness Care Program
Number of subjects: 278
Study 29107928 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical practice with free eye movements
Number of subjects: 0
Study 29107928 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational practice with free eye movements
Number of subjects: 0
Study 29107928 — intervention group
Group type: COMPARATOR
Intervention: Physical practice with instructed fixation
Number of subjects: 0
Study 29107928 — intervention group
Group type: COMPARATOR
Intervention: Observational practice with instructed fixation
Number of subjects: 0
Study 26857821 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection associated to radiographic examination
Number of subjects: 250
Study 26857821 — intervention group
Group type: COMPARATOR
Intervention: Visual inspection performed alone
Number of subjects: 250
Study 24826958 — intervention group
Group type: EXPERIMENTAL
Intervention: Three positive things in life intervention
Number of subjects: 10
Study 24826958 — intervention group
Group type: EXPERIMENTAL
Intervention: Value in Action (VIA) signature strengths intervention
Number of subjects: 10
Study 24826958 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 22795291 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training intervention
Number of subjects: 0
Study 22795291 — intervention group
Group type: COMPARATOR
Intervention: Diet pattern adhering to American Heart Association recommendations
Number of subjects: 0
Study 21123342 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated intervention (systematic health education, intensive and individualised intervention, treatment, and rehabilitation)
Number of subjects: 872
Study 21123342 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated intervention
Number of subjects: 872
Study 21123342 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 872
Study 17220745 — intervention group
Group type: EXPERIMENTAL
Intervention: HUD‐VASH (with Section 8 vouchers and intensive case management)
Number of subjects: 460
Study 17220745 — intervention group
Group type: COMPARATOR
Intervention: Case management only
Number of subjects: 460
Study 17220745 — intervention group
Group type: COMPARATOR
Intervention: Standard VA care
Number of subjects: 460
Study 15669709 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage procedure with a two-piece implant and a 3-month healing period (Group A)
Number of subjects: 108
Study 15669709 — intervention group
Group type: COMPARATOR
Intervention: Two-stage procedure with a two-piece implant and a 3-month healing period (Group B - Control Group)
Number of subjects: 108
Study 15669709 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage procedure with a one-piece implant and a 3-month healing period (Group C)
Number of subjects: 108
Study 15669709 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage surgical procedure with a two-piece implant and early loading (within 3 weeks) (Group D)
Number of subjects: 108
Study 15669709 — intervention group
Group type: COMPARATOR
Intervention: Two-stage surgery (Group B - Control Group)
Number of subjects: 108
Study 11843516 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG + mitral annuloplasty
Number of subjects: 0
Study 11843516 — intervention group
Group type: COMPARATOR
Intervention: CABG alone
Number of subjects: 0
Study 11352436 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 100mg twice daily
Number of subjects: 30
Study 11352436 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 200mg twice daily
Number of subjects: 30
Study 11352436 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg once daily
Number of subjects: 30
Study 11352436 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 600mg once daily
Number of subjects: 30
Study 11352436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9229034 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimanic treatment (specifics not provided)
Number of subjects: 27
Study 8105716 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.105 mg/kg MIV (1.5 x ED95) and H1/H2 antagonist
Number of subjects: 48
Study 8105716 — intervention group
Group type: COMPARATOR
Intervention: 0.105 mg/kg MIV and placebo
Number of subjects: 48
Study 8105716 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.21 mg/kg MIV (3 x ED95) and H1/H2 antagonist
Number of subjects: 48
Study 8105716 — intervention group
Group type: COMPARATOR
Intervention: 0.21 mg/kg MIV and placebo
Number of subjects: 48
Study 8105716 — intervention group
Group type: EXPERIMENTAL
Intervention: H1/H2 premedication
Number of subjects: 48
Study 8105716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 3145665 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 800 micrograms, q.i.d. for 4 weeks
Number of subjects: 116
Study 3145665 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 1200 mg, q.i.d. for 4 weeks
Number of subjects: 116
Study 28648577 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap-assisted colonoscopy (CAC)
Number of subjects: 203
Study 28648577 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy (SC)
Number of subjects: 203
Study 27793166 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b therapy at 1.5 mcg/kg for 48 weeks
Number of subjects: 171
Study 27793166 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg <1500 IU/mL at week 12
Number of subjects: 171
Study 27793166 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg decrease >1.5 logIU/mL at week 12
Number of subjects: 171
Study 27793166 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg >20,000 IU/mL at week 12
Number of subjects: 171
Study 27793166 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg >20,000 IU/mL at week 24
Number of subjects: 171
Study 27793166 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg level or changes at weeks 12 and 24 combined with HBeAg or HBV DNA
Number of subjects: 171
Study 24346752 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 15 mg
Number of subjects: 43
Study 24346752 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 20 mg
Number of subjects: 43
Study 24346752 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 2 to 6 mg
Number of subjects: 43
Study 24346752 — intervention group
Group type: COMPARATOR
Intervention: Risperidone and Olanzapine groups
Number of subjects: 43
Study 24346752 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 43
Study 24346752 — intervention group
Group type: COMPARATOR
Intervention: All drug groups
Number of subjects: 43
Study 24188719 — intervention group
Group type: EXPERIMENTAL
Intervention: LINDA intervention (n = 1,537) received a 20‐minute individualized lifestyle counseling session followed by further support at six‐monthly follow-ups for 1.5‐2.5 years.
Number of subjects: 3059
Study 24188719 — intervention group
Group type: EXPERIMENTAL
Intervention: Support on healthy physical activity behaviors.
Number of subjects: 3059
Study 24188719 — intervention group
Group type: EXPERIMENTAL
Intervention: Support on healthy sleeping behaviors.
Number of subjects: 3059
Study 24188719 — intervention group
Group type: EXPERIMENTAL
Intervention: Support on healthy dietary behaviors.
Number of subjects: 3059
Study 24188719 — intervention group
Group type: COMPARATOR
Intervention: Control group (received counseling on sexual health and contraception).
Number of subjects: 3059
Study 21109113 — intervention group
Group type: EXPERIMENTAL
Intervention: Erectile dysfunction (ED) at baseline
Number of subjects: 6304
Study 18423009 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral melatonin 10 mg administered at 9 p.m. for four nights
Number of subjects: 24
Study 18423009 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered at 9 p.m. for four nights
Number of subjects: 24
Study 15847226 — intervention group
Group type: EXPERIMENTAL
Intervention: Feature generation task (Experiment 1)
Number of subjects: 0
Study 15847226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued recall task (Experiment 2)
Number of subjects: 0
Study 15847226 — intervention group
Group type: EXPERIMENTAL
Intervention: Feature verification tasks (Experiment 3)
Number of subjects: 0
Study 15847226 — intervention group
Group type: EXPERIMENTAL
Intervention: Feature verification tasks with priming biases minimized (Experiment 4)
Number of subjects: 0
Study 12528027 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Care Information System (ICIS)
Number of subjects: 145
Study 12528027 — intervention group
Group type: COMPARATOR
Intervention: Paper-based registration
Number of subjects: 145
Study 10574164 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective swelling of the hand
Number of subjects: 186
Study 10574164 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive electrodiagnostic findings
Number of subjects: 186
Study 10574164 — intervention group
Group type: EXPERIMENTAL
Intervention: Phalen test and carpal compression test
Number of subjects: 186
Study 8916314 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin (IDA) 12 mg/m2/d for 3 days and cytosine arabinoside (Ara‐C) 100 mg/m2/d for 7 days
Number of subjects: 26
Study 1858985 — intervention group
Group type: COMPARATOR
Intervention: Placebo pretreatment before tracheal extubation
Number of subjects: 25
Study 1858985 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1 mg/kg IV) pretreatment before tracheal extubation
Number of subjects: 25
Study 30820037 — intervention group
Group type: EXPERIMENTAL
Intervention: Persons with NF1
Number of subjects: 550
Study 28932131 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with subdiaphragmatic lidocaine
Number of subjects: 84
Study 28932131 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 84
Study 28932131 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 84
Study 26905266 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine modified-release tablets (MR group, n = 126)
Number of subjects: 251
Study 26905266 — intervention group
Group type: COMPARATOR
Intervention: Other enteric-coated tablets (EC group, n = 125)
Number of subjects: 251
Study 25134737 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-salt exposure
Number of subjects: 135
Study 25134737 — intervention group
Group type: COMPARATOR
Intervention: Regular-salt exposure
Number of subjects: 135
Study 25134737 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating reduced- and regular-salt exposure
Number of subjects: 135
Study 25134737 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradually declining salt concentration exposure
Number of subjects: 135
Study 25134737 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 135
Study 21512102 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive reading intervention (50-minute daily sessions in groups of 2-4 students)
Number of subjects: 41
Study 21512102 — intervention group
Group type: COMPARATOR
Intervention: No researcher-provided intervention (comparison group)
Number of subjects: 41
Study 19175878 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine + vaccine + HBIg
Number of subjects: 150
Study 19175878 — intervention group
Group type: COMPARATOR
Intervention: placebo + vaccine + HBIg
Number of subjects: 150
Study 17722445 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol plus dexamethasone
Number of subjects: 49
Study 17722445 — intervention group
Group type: COMPARATOR
Intervention: Nebulized salbutamol
Number of subjects: 49
Study 15889321 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial aspart insulin
Number of subjects: 18
Study 15889321 — intervention group
Group type: COMPARATOR
Intervention: Preprandial aspart insulin
Number of subjects: 18
Study 15889321 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preprandial and postprandial aspart insulin
Number of subjects: 18
Study 12529065 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced standard program (two short individual sessions and a brief follow-up session)
Number of subjects: 4074
Study 12529065 — intervention group
Group type: COMPARATOR
Intervention: Standard first-offender program
Number of subjects: 4074
Study 12529065 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced standard program
Number of subjects: 4074
Study 9698977 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 120
Study 9698977 — intervention group
Group type: EXPERIMENTAL
Intervention: Food
Number of subjects: 120
Study 9698977 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal expectancy manipulation
Number of subjects: 120
Study 9698977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 8620667 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton (800mg)
Number of subjects: 24
Study 8620667 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (500mg)
Number of subjects: 24
Study 8620667 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of zileuton and naproxen
Number of subjects: 24
Study 8620667 — intervention group
Group type: COMPARATOR
Intervention: Zileuton
Number of subjects: 24
Study 8620667 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 24